Tempest Financial Statements From 2010 to 2025

TPST Stock  USD 8.08  0.32  4.12%   
Analyzing historical trends in various income statement and balance sheet accounts from Tempest Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tempest Therapeutics' valuation are summarized below:
Market Capitalization
28.6 M
Earnings Share
(18.04)
There are currently one hundred twenty fundamental trend indicators for Tempest Therapeutics that can be evaluated and compared over time across competition. All traders should double-check Tempest Therapeutics' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 105.1 M in 2025. Enterprise Value is likely to gain to about 65.6 M in 2025

Tempest Therapeutics Total Revenue

0.0

Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 37.3 M, Research Development of 19 M or Total Operating Expenses of 37.2 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 16.62. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Tempest Stock
Check out the analysis of Tempest Therapeutics Correlation against competitors.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Tempest Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets64.9 M41.5 M56 M
Pretty Stable
Other Current Liabilities6.1 M3.5 M5.3 M
Pretty Stable
Total Current Liabilities9.7 M14.2 M8.4 M
Slightly volatile
Accounts Payable1.3 M2.5 M1.5 M
Pretty Stable
Cash35.8 M30.3 M31 M
Slightly volatile
Cash And Short Term Investments43.5 M30.3 M50.6 M
Very volatile
Common Stock Total Equity22.8 K21.9 K19.4 K
Slightly volatile
Liabilities And Stockholders Equity64.9 M41.5 M56 M
Pretty Stable
Non Current Liabilities Total12.3 M8.1 M10.5 M
Slightly volatile
Other Stockholder Equity139.6 M226.2 M119.8 M
Slightly volatile
Total Liabilities15.2 M22.4 M13.1 M
Slightly volatile
Total Current Assets43.3 M31.5 M50.3 M
Very volatile
Common Stock46.2 K44 K20.1 K
Slightly volatile
Property Plant And Equipment NetM9.5 M4.8 M
Slightly volatile
Non Current Assets Total5.8 M10 M4.7 M
Slightly volatile
Common Stock Shares Outstanding29.3 M27.9 M4.7 M
Slightly volatile
Short Term Investments4.8 MM23.2 M
Slightly volatile
Property Plant And Equipment Gross6.2 M10.8 M4.9 M
Slightly volatile
Short and Long Term Debt Total11.7 M15.4 M6.4 M
Slightly volatile
Current Deferred Revenue267.2 K300.6 K327.7 K
Slightly volatile
Net Receivables491.6 K517.5 K1.8 M
Pretty Stable
Inventory1.9 M1.8 M658 K
Slightly volatile
Short Term Debt7.6 M7.2 M1.7 M
Slightly volatile
Property Plant EquipmentM4.8 M3.9 M
Slightly volatile
Capital Lease Obligations8.1 MM4.3 M
Slightly volatile
Capital Stock46.2 K44 K8.8 K
Slightly volatile
Net Working Capital22.3 M17.3 M20.5 M
Slightly volatile
Long Term Debt8.5 M5.6 M13.2 M
Slightly volatile
Short and Long Term Debt5.9 M6.4 M4.5 M
Slightly volatile

Tempest Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses37.3 M33.5 M32.1 M
Pretty Stable
Research Development19 M28.1 M16.4 M
Slightly volatile
Total Operating Expenses37.2 M42 M32.1 M
Pretty Stable
Depreciation And Amortization369.6 K389 K664.7 K
Pretty Stable
Selling General Administrative15.6 M13.6 M17.7 M
Pretty Stable
Cost Of Revenue369.6 K389 K922.5 K
Very volatile
Selling And Marketing Expenses325.8 K342.9 K12.3 M
Slightly volatile
Interest Income1.6 M1.5 M361.5 K
Slightly volatile
Reconciled Depreciation495.7 K389 K383.7 K
Slightly volatile

Tempest Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.1 M5.3 M4.6 M
Pretty Stable
Begin Period Cash Flow31.1 M39.7 M25.5 M
Slightly volatile
Depreciation563.3 K389 K618.9 K
Very volatile
Capital Expenditures860.1 K435 KM
Slightly volatile
End Period Cash Flow38.4 M30.7 M32.6 M
Slightly volatile
Net Borrowings12 M13.5 M14.7 M
Slightly volatile
Issuance Of Capital Stock18.3 M28.6 M30.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.361.4397.2816
Slightly volatile
Days Sales OutstandingK1.1 K1.3 K
Slightly volatile
Book Value Per Share0.650.6855K
Slightly volatile
Stock Based Compensation To Revenue21.7121.0318.5372
Slightly volatile
Capex To Depreciation1.061.11832.9669
Slightly volatile
Payables Turnover0.410.45090.4303
Pretty Stable
Sales General And Administrative To Revenue71.6784.6468.107
Slightly volatile
Research And Ddevelopement To Revenue30.2344.3233.1318
Slightly volatile
Capex To Revenue0.01480.01561.5252
Pretty Stable
Cash Per Share1.031.08486.8 K
Slightly volatile
Days Payables Outstanding6927294.5 K
Very volatile
Income Quality0.620.78930.769
Pretty Stable
Net Debt To EBITDA0.350.37130.9079
Slightly volatile
Current Ratio2.12.21346.5559
Slightly volatile
Tangible Book Value Per Share0.650.6855K
Slightly volatile
Receivables Turnover0.230.260.281
Slightly volatile
Capex Per Share0.01480.015686.6228
Slightly volatile
Graham Net Net0.270.28336.4 K
Slightly volatile
Revenue Per Share239227170
Slightly volatile
Interest Debt Per Share0.520.550754.7149
Very volatile
Debt To Assets0.390.37030.1487
Slightly volatile
Operating CycleK1.1 K1.3 K
Slightly volatile
Days Of Payables Outstanding6927294.5 K
Very volatile
Ebt Per Ebit1.390.99561.2384
Very volatile
Long Term Debt To Capitalization0.140.170.1972
Very volatile
Quick Ratio2.12.21346.5559
Slightly volatile
Net Income Per E B T1.111.141.0194
Slightly volatile
Cash Ratio2.022.12864.3066
Slightly volatile
Days Of Sales OutstandingK1.1 K1.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.01321.0433
Slightly volatile
Fixed Asset Turnover0.10.110.9675
Slightly volatile
Debt Ratio0.390.37030.1487
Slightly volatile
Price Sales Ratio1.361.4397.2816
Slightly volatile
Asset Turnover0.01630.01710.0555
Slightly volatile

Tempest Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap105.1 M78 M99.1 M
Very volatile

Tempest Fundamental Market Drivers

Cash And Short Term Investments30.3 M

Tempest Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tempest Therapeutics Financial Statements

Tempest Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue300.6 K267.2 K
Cost Of Revenue389 K369.6 K
Stock Based Compensation To Revenue 21.03  21.71 
Sales General And Administrative To Revenue 84.64  71.67 
Research And Ddevelopement To Revenue 44.32  30.23 
Capex To Revenue 0.02  0.01 
Revenue Per Share 227.31  238.68 
Ebit Per Revenue(79.85)(83.84)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.